Literature DB >> 15073920

Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts.

M S Duh1, A M Walker, K H Kronlund.   

Abstract

OBJECTIVES: This study quantifies the incidence of liver enzyme abnormalities in the general population of central Massachusetts.
METHODS: Computerized data files from a health maintenance organization were used to ascertain potential subjects during the study period of 1 July 1992-30 June 1993. Medical records and laboratory tests results were reviewed to confirm the diagnoses.
RESULTS: The incidence rates were 40.6 cases per 100,000 persons per year for drug-associated liver enzyme abnormalities, 39.0 per 100,000 persons per year for liver enzyme abnormalities secondary to biliary pathologies, 25.2 per 100,000 persons per year for liver enzyme abnormalities secondary to mononucleosis, 25.2 per 100,000 persons per year for liver enzyme abnormalities of unknown aetiology, 15.4 per 100,000 persons per year for alcoholic liver enzyme abnormalities, 12.2 per 100,000 persons per year for liver malignancy, and 7.3 per 100,000 persons per year for viral hepatitis (HAV, HBV and HCV). Men were more commonly affected by alcoholic liver enzyme abnormalities and viral hepatitis, with respective incidence rates approximately 5 and 2 times higher than women. Liver enzyme abnormalities secondary to mononucleosis occurred predominantly between the ages of 15-24 years. In contrast, liver diseases secondary to biliary pathologies, liver malignancies and drug-associated liver enzyme abnormalities were found most frequently among the elderly.
CONCLUSION: Liver enzyme abnormalities occurred with a higher incidence in this general population than reported previously in selected patients. Drug-associated liver enzyme abnormality was the most common type. The magnitude of drug-associated liver enzyme abnormality could be much higher as an appreciable proportion of the liver cases of unknown aetiology are potentially drug-attributable. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Year:  1999        PMID: 15073920     DOI: 10.1002/(SICI)1099-1557(199907)8:4<275::AID-PDS427>3.0.CO;2-D

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  9 in total

1.  A Text Searching Tool to Identify Patients with Idiosyncratic Drug-Induced Liver Injury.

Authors:  Lauren Heidemann; James Law; Robert J Fontana
Journal:  Dig Dis Sci       Date:  2015-11-23       Impact factor: 3.199

Review 2.  Drug-induced liver injury: review article.

Authors:  Wissam Bleibel; Stephen Kim; Karl D'Silva; Eric R Lemmer
Journal:  Dig Dis Sci       Date:  2007-03-16       Impact factor: 3.199

Review 3.  Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.

Authors:  Robert J Fontana
Journal:  Gastroenterology       Date:  2013-12-31       Impact factor: 22.682

4.  A new Poisson and Bayesian-based method to assign risk and causality in patients with suspected hepatic adverse drug reactions: a report of two new cases of ticlopidine-induced hepatotoxicity.

Authors:  Pedro Zapater; José Such; Miguel Pérez-Mateo; José Francisco Horga
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

5.  Idiopathic acute liver injury in paediatric outpatients: incidence and signal detection in two European countries.

Authors:  Carmen Ferrajolo; Katia M C Verhamme; Gianluca Trifirò; Geert W 't Jong; Carlo Giaquinto; Gino Picelli; Alessandro Oteri; Sandra de Bie; Vera E Valkhoff; Martijn J Schuemie; Giampiero Mazzaglia; Claudio Cricelli; Francesco Rossi; Annalisa Capuano; Miriam C J M Sturkenboom
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

6.  Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder.

Authors:  Mark E Bangs; Ling Jin; Shuyu Zhang; Durisala Desaiah; Albert J Allen; Holly A Read; Arie Regev; Joachim F Wernicke
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 7.  Epidemiology of idiosyncratic drug-induced liver injury.

Authors:  Lauren N Bell; Naga Chalasani
Journal:  Semin Liver Dis       Date:  2009-10-13       Impact factor: 6.115

8.  Development of a decision support tool to facilitate primary care management of patients with abnormal liver function tests without clinically apparent liver disease [HTA03/38/02]. Abnormal Liver Function Investigations Evaluation (ALFIE).

Authors:  Peter T Donnan; David McLernon; Douglas Steinke; Stephen Ryder; Paul Roderick; Frank M Sullivan; William Rosenberg; John F Dillon
Journal:  BMC Health Serv Res       Date:  2007-04-16       Impact factor: 2.655

9.  Guidelines on the management of abnormal liver blood tests.

Authors:  Philip N Newsome; Rob Cramb; Suzanne M Davison; John F Dillon; Mark Foulerton; Edmund M Godfrey; Richard Hall; Ulrike Harrower; Mark Hudson; Andrew Langford; Anne Mackie; Robert Mitchell-Thain; Karen Sennett; Nicholas C Sheron; Julia Verne; Martine Walmsley; Andrew Yeoman
Journal:  Gut       Date:  2017-11-09       Impact factor: 23.059

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.